A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials

DOI10.1080/07474946.2016.1238250MaRDI QIDQ2958397zbMATH OpenOpenAlexWikidataFDO

Authors Steven B. Kim, Daniel L. Gillen

Publication date 1 February 2017

Published in Sequential Analysis (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/07474946.2016.1238250

zbMATH Keywords

phase I clinical trialsadaptive designindividual- and population-level ethicsmultiple Bayesian adaptive designs

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Sequential statistical design (62L05) Bayesian problems; characterization of Bayes procedures (62C10)

Recommendations

• Incorporating individual and collective ethics into phase I cancer trial designs
• Bayesian optimal designs for phase I clinical trials
• The treatment versus experimentation dilemma in dose finding studies
• A new design of the continual reassessment method
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs

Cites work

• Approximate dynamic programming and its applications to the design of Phase I cancer trials
• Bayesian decision procedures based on logistic regression models for dose-finding studies
• Bayesian optimal designs for phase I clinical trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Continual reassessment and related dose-finding designs
• Design and Analysis of Phase I Clinical Trials
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Incorporating individual and collective ethics into phase I cancer trial designs
• Penalized optimal designs for dose-finding

Cited in

(2)

• A Bayesian design for phase I cancer therapeutic vaccine trials
• Incorporating individual and collective ethics into phase I cancer trial designs

This page was built for publication: A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2958397)